March 12, 2019
- FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma - Transcript
- FDA D.I.S.C.O.: FDA approval of cabozantinib for hepatocellular carcinoma - Mp3 file
- Cancer Clinical Trial Eligibility Criteria: Patients with Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infections; Guidance for Industry (PDF - 313KB)
- Cancer Clinical Trial Eligibility Criteria: Minimum Age for Pediatric Patients; Guidance for Industry (PDF - 286KB)
- Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies;Guidance for Industry (PDF - 281KB)
- Cancer Clinical Trial Eligibility Criteria: Brain Metastases; Guidance for Industry (PDF - 274KB)
- Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials; Guidance for Industry (PDF - 87KB)
- Drugs@FDA Data Files (updated)
- FDA Drug Shortages
- Hydroxyzine Pamoate Oral Capsules (New - Currently in Shortage)
- Hydroxyprogesterone Caproate Injection (Updated - Currently in Shortage)
- Olmesartan Medoxomil Tablets (New - Currently in Shortage)
No hay comentarios:
Publicar un comentario